In patients with allergic rhinitis, Diethylcarbamazine is an effective adjuvant to antihistamines that reduces the severity of symptoms.

A comparative research was conducted to evaluate the efficiency of Diethylcarbamazine in lowering        symptoms in individuals with allergic rhinitis when combined with an antihistaminic therapy.

In this single-blind randomized controlled trial, 50 allergic rhinitis patients aged 13-60 years served as cases and 50 patients served as controls. Patients were classified as severe, moderate and mild, based on the symptom severity.

For a period of 21 days, the patients in the case group were given tablet Cetrizine 10 mg and tablet Diethylcarbamazine 300 mg. Placebo along with Cetrizine 10 mg was given to the control group. Observation continued for three months to see any improvement in the symptoms and the results were compared.

Out of 50 patients in the case group, 20 cases showed improvement and 30 cases did not show any signs of improvement. Out of 50 controls, only 6 showed improvement whereas 44 didn’t show any signs of improvement.

As an adjuvant, the antifilarial medication Diethylcarbamazine effectively reduces inflammatory mediators and is beneficial to lower the intensity of symptoms in allergic rhinitis.